Amarin Corp Plc (AMRN)

[ziploc_1]

From the FDA letter:" FDA also noted the unusual combination of circumstances presented, including, but not limited to, the design and results of the ANCHOR trial, the rescission of the ANCHOR SPA agreement based on the developing science, the safety profile of Vascepa, and Amarin's commitment to complete the REDUCE-IT trial.".....A reasomable inference from this is that Amarin's commitment to complete the REDUCE-IT trial might be negatively influenced by Anchor approval and might be connected to why the FDA rescinded the SPA.